Literature DB >> 16130895

Tumor angiogenesis and molecular target therapy in ovarian carcinomas.

Masatsugu Ueda1, Yoshito Terai, Koji Kanda, Masanori Kanemura, Mikio Takehara, Hikari Futakuchi, Hiroyuki Yamaguchi, Masayuki Yasuda, Koji Nishiyama, Minoru Ueki.   

Abstract

Growth of solid tumors depends on angiogenesis, the process by which new blood vessels develop from the endothelium of a pre-existing vasculature. Tumors promote angiogenesis by secreting various angiogeneic factors, and newly formed blood vessels induce tumor cell proliferation and invasiveness. Ovarian carcinomas have a poor prognosis, often associated with multifocal intraperitoneal dissemination accompanied by intense neovascularization. The degree of angiogenesis of ovarian carcinomas may directly influence the clinical course of the disease. Although a growing body of evidence indicates that angiogenic intensity may play a prognostic role in gynecological malignancies including ovarian carcinomas, the related biological mechanisms remain to be further elucidated. In this review, we describe current knowledge pertaining to mechanisms and regulation of angiogenesis in ovarian carcinomas with special reference to our recent research results.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16130895     DOI: 10.1111/j.1749-0774.2005.tb00052.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  42 in total

1.  Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.

Authors:  N Abramson; P K Stokes; Mathew Luke; Alan R Marks; Jeffrey M Harris
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

2.  Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells.

Authors:  M Ueda; Y Terai; K Kumagai; K Ueki; M Kanemura; M Ueki
Journal:  Int J Cancer       Date:  2001-03-15       Impact factor: 7.396

3.  Angiogenesis in primary and metastatic epithelial ovarian carcinoma.

Authors:  O Abulafia; W E Triest; D M Sherer
Journal:  Am J Obstet Gynecol       Date:  1997-09       Impact factor: 8.661

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas.

Authors:  Masatsugu Ueda; Yao-Ching Hung; Yoshito Terai; Koji Kanda; Masanori Kanemura; Hikari Futakuchi; Hiroyuki Yamaguchi; Daisuke Akise; Masayuki Yasuda; Minoru Ueki
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

6.  Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.

Authors:  J Kandel; E Bossy-Wetzel; F Radvanyi; M Klagsbrun; J Folkman; D Hanahan
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

7.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.

Authors:  R Valtola; P Salven; P Heikkilä; J Taipale; H Joensuu; M Rehn; T Pihlajaniemi; H Weich; R deWaal; K Alitalo
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

8.  Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas.

Authors:  Masatsugu Ueda; Yoshito Terai; Yoshiki Yamashita; Koji Kumagai; Ken Ueki; Hiroyuki Yamaguchi; Daisuke Akise; Yao-Ching Hung; Minoru Ueki
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

9.  Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract.

Authors:  H Ohtani; S Nakamura; Y Watanabe; T Mizoi; T Saku; H Nagura
Journal:  Lab Invest       Date:  1993-05       Impact factor: 5.662

10.  Thymidine phosphorylase is angiogenic and promotes tumor growth.

Authors:  A Moghaddam; H T Zhang; T P Fan; D E Hu; V C Lees; H Turley; S B Fox; K C Gatter; A L Harris; R Bicknell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

View more
  6 in total

1.  Up-regulated EMMPRIN/CD147 protein expression might play a role in colorectal carcinogenesis and its subsequent progression without an alteration of its glycosylation and mRNA level.

Authors:  Hua-chuan Zheng; Wei Wang; Xiao-yan Xu; Pu Xia; Miao Yu; Toshiro Sugiyama; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-01       Impact factor: 4.553

2.  The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.

Authors:  P M O'Brien; M J Davies; J P Scurry; A N Smith; C A Barton; M J Henderson; D N Saunders; B S Gloss; K I Patterson; J L Clancy; V A Heinzelmann-Schwarz; Rajmohan Murali; R A Scolyer; Y Zeng; E D Williams; L Scurr; A Defazio; D I Quinn; C K W Watts; N F Hacker; S M Henshall; R L Sutherland
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

3.  Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis.

Authors:  H-C Zheng; H Takahashi; Y Murai; Z-G Cui; K Nomoto; S Miwa; K Tsuneyama; Y Takano
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

Review 4.  Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.

Authors:  Yuliya Klymenko; Oleg Kim; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2017-08-09       Impact factor: 6.639

5.  Knockdown of growth factor receptor bound protein 7 suppresses angiogenesis by inhibiting the secretion of vascular endothelial growth factor A in ovarian cancer cells.

Authors:  Qiong Xu; Zequn Liu; Zhi-Qin Zhu; Yue Fan; Rui Chen; Xiao-Hui Xie; Mi Cheng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  The role of EMMPRIN expression in ovarian epithelial carcinomas.

Authors:  Yang Zhao; Shuo Chen; Wen-feng Gou; Zhe-feng Niu; Shuang Zhao; Li-jun Xiao; Yasuo Takano; Hua-chuan Zheng
Journal:  Cell Cycle       Date:  2013-08-08       Impact factor: 4.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.